Skip to main content
SpringerLink
Log in

Age is just a number with ulcerative colitis therapies

  • Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Limited data suggest that older patients with ulcerative colitis (UC) irrespective of late-onset UC or disease diagnosed before the age of 60 years, should largely receive similar corticosteroid-sparing agents to as those prescribed to younger patients. Typically, mesalamine is recommended as a first-line agent for induction or maintenance therapy, with biological treatments recommended for more severe disease. The risk profile for adverse drug events should be taken into consideration when selecting an appropriate therapy, for example, immunosuppressants may exacerbate infection risks.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Raine T, Bonovas S, Burisch J, et al. ECCO guidelines on therapeutics in ulcerative colitis: medical treatment. J Crohns Colitis. 2022;16(1):2–17.

    Article  PubMed  Google Scholar 

  2. Feuerstein JD, Isaacs KL, Schneider Y, et al. AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis. Gastroenterology. 2020;158(5):1450–61.

    Article  PubMed  Google Scholar 

  3. Sturm A, Maaser C, Mendall M, et al. European Crohn’s and Colitis Organisation topical review on IBD in the elderly. J Crohns Colitis. 2017;11(3):263–73.

    PubMed  Google Scholar 

  4. Fries W, Demarzo MG, Navarra G, et al. Ulcerative colitis in adulthood and in older patients: same disease, same outcome, same risks? Drugs Aging. 2022;39(6):441–52.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Vieujean S, Caron B, Jairath V, et al. Is it time to include older adults in inflammatory bowel disease trials? A call for action. Lancet Healthy Longev. 2022;3(5):e356–66.

    Article  PubMed  Google Scholar 

  6. Kochar B, Kalasapudi L, Ufere NN, et al. Systematic review of inclusion and analysis of older adults in randomized controlled trials of medications used to treat inflammatory bowel diseases. Inflamm Bowel Dis. 2021;27(9):1541–3.

    Article  PubMed  Google Scholar 

  7. Ko CW, Singh S, Feuerstein JD, et al. AGA clinical practice guidelines on the management of mild-to-moderate ulcerative colitis. Gastroenterology. 2019;156(3):748–64.

    Article  PubMed  Google Scholar 

  8. U.S. Pharmaceuticals. XELJANZ (tofacitinib): US prescribing information. 2012. https://dailymed.nlm.nih.gov/. Accessed 30 Mar 2023.

  9. European Medicines Authority. EMA confirms Xeljanz to be used with caution in patients at high risk of blood clots. 2019. https://www.ema.europa.eu/. Accessed 29 Mar 2023.

  10. Matsuoka K, Igarashi A, Sato N, et al. Trends in corticosteroid prescriptions for ulcerative colitis and factors associated with long-term corticosteroid use: analysis using Japanese claims data from 2006 to 2016. J Crohns Colitis. 2021;15(3):358–66.

    Article  PubMed  Google Scholar 

  11. AbbVie Inc. HUMIRA (adalimumab): US prescribing information. 2002. https://dailymed.nlm.nih.gov/. Accessed 3 Apr 2022.

  12. Janssen Biotech Inc. STELARA (ustekinumab): US prescribing information. 2009. https://dailymed.nlm.nih.gov/. Accessed 30 Mar 2023.

  13. Takeda Pharmaceuticals America Inc. ENTYVIO (vedolizumab): US prescribing information. 2014. https://dailymed.nlm.nih.gov/. Accessed 29 Mar 2023.

  14. Janssen Biotech Inc. SIMPONI (golimumab): US prescribing information. 2009. https://dailymed.nlm.nih.gov/. Accessed 3 Apr 2023.

  15. Janssen Biotech Inc. REMICADE (infliximab): US prescribing information. 1998. https://dailymed.nlm.nih.gov/. Accessed 29 Mar 2023.

  16. Kuenzig ME, Manuel DG, Donelle J, et al. Real world evidence of the association between medication and life expectancy in elderly inflammatory bowel disease: a population-based cohort study. BMC Gastroenterol. 2022;22(1):5.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Takeda Pharmaceuticals America Inc. PENTASA (mesalamine): US prescribing information. 2004. https://dailymed.nlm.nih.gov/. Accessed 30 Mar 2023.

  18. Brassard P, Bitton A, Suissa A, et al. Oral corticosteroids and the risk of serious infections in patients with elderly-onset inflammatory bowel diseases. Am J Gastroenterol. 2014;109(11):1795–802.

    Article  CAS  PubMed  Google Scholar 

  19. Toruner M, Loftus EV, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134(4):929–36.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand

    Caroline Fenton & Arnold Lee

Authors
  1. Caroline Fenton
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Arnold Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Arnold Lee.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Authorship and conflict of interest

C Fenton, a contracted employee of Adis International Ltd/Springer Nature, and A Lee, a salaried employee of Adis International Ltd/Springer Nature, declare no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.

Ethics approval, Consent to participate, Consent for publication, Availability of data and material, Code availability

Not applicable.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fenton, C., Lee, A. Age is just a number with ulcerative colitis therapies. Drugs Ther Perspect 39, 243–247 (2023). https://doi.org/10.1007/s40267-023-01007-y

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40267-023-01007-y

Search

Navigation